. Author manuscript; available in PMC: 2012 Mar 24.

Published in final edited form as: Kidney Int. 2011 Aug 17;80(9):992–999. doi: 10.1038/ki.2011.247

Table 4.

Association of variant hemoglobin and alternative definitions for higher-dose ESA

	Variant hemoglobin
	N	OR (95% CI)	P
Definition for higher-dose ESA^a
≥6000 U/treatment	14/33	2.96 (1.09–8.01)	0.03
≥6500 U/treatment	14/33	3.31 (1.20–9.11)	0.02
≥7000 U/treatment	13/33	4.15 (1.40–12.33)	0.01
≥8000 U/treatment	9/33	2.43 (0.74–7.98)	0.1
≥9000 U/treatment	7/33	1.92 (0.58–6.30)	0.3
≥10,000 U/treatment	7/33	2.16 (0.65–7.21)	0.2
Weight-based definition for higher-dose ESA
≥100 U/kg/treatment^a	11/33	2.67 (0.93–7.66)	0.07
≥100 U/kg/treatment^b	11/33	2.74 (1.08–6.91)	0.03

Abbreviations: CI, confidence interval; ESA, erythropoiesis-stimulating agent; OR, odds ratio.

Multivariate analysis adjusted for percent of missed treatments, albumin, dialysis access, dialysis vintage, Kt/V, ferritin, iron saturation, iPTH, dialysis unit, history of gastrointestinal bleeding, and iron dose per treatment.

Adjusted for percent of missed treatments, albumin, and dialysis access.

The bold row represents the primary outcome definition for higher-dose ESA used in the initial analysis.